3Katano M,Morisaki T. The past,the present and future of the OK-432 therapy for patients with malignant effusions. Anticancer Res, 1998,18(5D) :3 917
4Tanaka N,Gouchi A,Ohara T,et al. Intratumoral injection of a streptococcal preparation, OK-432,before surgery for gastric cancer. Cancer,1994,74(12) :3 097
1Raft Janajreh AQ, Chen D, Schmits R, et al. Evidence for the involvement of CD44 in endothelial cell injury and induction of vascular leak syndrome by IL-2 [ J ]. J Immunol, 1999,163(3) :1 619.
2Powell S, Dudek AZ. Single-institution outcome of highdose interleukin-2 ( HD IL-2) therapy for metastatic melanoma and analysis of favorable response in brain metastases [ J ]. Anticancer Res, 2009,29 ( 10 ) : 4 189.
3Llarena Ibarguren R. Treatment of metastatic renal cancer: current validity of immunotherapy [ J ]. Actas Urol Esp, 2009,33 (5) :584.
4Tarhini AA, Kirkwood JM, Gooding WE, et al. Durable complete responses with high-dose bolus interleukin-2 in patients with metastatic melanoma who have experienced progression after bioehemotherapy [ J ]. J Clin Oncol,2007 , 25(25) :3 802.
5Yamanaka K, Saito J, Nakata W, et al. Case of drug-induced colitis like ulcerative colitis during IL-2 therapy for multiple bone metastasis after operation of kidney cancer [ J ]. Nippon Hinyokika Gakkai Zasshi ,2009,100 (5) :586.
6Rosenberg SA, Mule JJ, Spiess PJ, et al. Regression of established pulmonary metastases and subcutaneous tumor mediated by the systemic administration of high-dose recombi- nant interleukin 2 [ J ]. J Exp Med, 1985,161 (5) : 1 169.
7Bukowski RM. Cytokine combinations: therapeutic use in patients with advanced renal cell carcinoma [ J ]. Semin in Oneol, 2000,27 ( 2 ) : 204.
